Healthcare >> CEO Interviews >> May 29, 2000

Gail Maderis – Genzyme Molecular Oncology (gzmo)

GAIL J. MADERIS is President of Genzyme Molecular Oncology. With more than 15 years of management experience in biotechnology and healthcare environments, Ms. Maderis possesses a diverse portfolio of knowledge and skills in business management, research and development, and gene therapy. In 1997, Ms. Maderis conceived and created Genzyme Molecular Oncology, one of Genzyme Corporation's three tracking stock divisions, which focuses on the development and commercialization of innovative therapeutics to treat cancer. During the process of creating the division, Ms. Maderis managed Genzyme's acquisition of PharmaGenics, Inc., and initiated the major partnerships that became the cornerstone of the business. Under her leadership, Genzyme Molecular Oncology has signed more than a dozen commercial agreements with pharmaceutical companies for use of its proprietary SAGE differential gene expression technology. The division also has formed business partnerships with world-class companies such as Purdue Pharma and the pharmaceutical division of Kirin Brewery, Japan. Additionally, it collaborates with several prominent academic and research organizations including the National Cancer Institute, The Johns Hopkins University, Dana-Farber Cancer Institute and Massachusetts General Hospital. Prior to forming Genzyme Molecular Oncology, Ms. Maderis was Vice President and Business Manager of Genzyme Corporation's cystic fibrosis and gene therapy programs. Prior to joining Genzyme, Ms. Maderis spent seven years as a Manager at Bain & Company, Inc., where she was responsible for developing and implementing major strategic programs for several large companies in the pharmaceutical and healthcare industries. She earned a Bachelor's degree with honors in Business Administration from the University of California, Berkeley in 1978 and received an MBA from Harvard Business School in 1985. Profile
TWST: Could we start out with an overview and a history of the company,

just to set the stage for readers?

Ms. Maderis: Genzyme Molecular Oncology is a tracking stock division of

Genzyme